“…Therefore, psoriasis could be treated by regulating Th17, and then inhibiting the secretion of related inflammatory factors. MPO was used as a marker of neutrophils, so reducing the level of MPO in psoriatic skin may be an appropriate method to reduce skin inflammation [ 20 ]. Neutrophils and the IL-17-producing Th17 subset of CD4 T cells have also a relationship [ 21 ].…”